Skip Navigation
Grant Details

Grant Number: 7R01CA116758-03 Interpret this number
Primary Investigator: Shahinian, Vahakn
Organization: University Of Michigan
Project Title: Gnrh Agonists for Prostate Cancer: Role of the Urologist
Fiscal Year: 2006
Back to top


Abstract

DESCRIPTION (provided by applicant): There is uncertainty regarding the efficacy of androgen deprivation therapy for earlier stages of prostate cancer. In addition, there are serious toxicities and a substantial financial cost associated with this therapy, particularly with the use of gonadotropin-releasing hormone (GnRH) agonists, which are now the predominant form of androgen deprivation. In the face of these concerns, recent studies have shown a dramatic rise in the use of GnRH agonists for prostate cancer over the 1990s, even in settings where there is no evidence of survival benefit. Wide differences in rates of GnRH agonist use between geographic regions suggest the presence of variations in practice patterns, possibly reflecting provider uncertainty about the risks and benefits of this therapy. We hypothesize that the provider plays an important role in influencing the observed time trends and variations in use of GnRH agonists for prostate cancer. This study will use linked SEER Medicare data and American Medical Association data to achieve the following objectives: 1) describe the variation among providers in use of GnRH agonists, 2) examine the effect of provider characteristics on the likelihood of use of GnRH agonists for prostate cancer and 3) determine the provider characteristics that influenced the change in use of GnRH agonists for prostate cancer over the 1990s. Collectively, the information derived from this proposal will help direct efforts at provider education and monitoring the use of GnRH agonists for prostate cancer. This will be especially important as more information on the risks and benefits of GnRH agonists become available, with the ultimate goal being the provision of quality care for men with prostate cancer.

Back to top


Publications

Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.
Authors: Gilbert SM, Kuo YF, Shahinian VB
Source: Urol Oncol, 2011 Nov-Dec;29(6), p. 647-53.
EPub date: 2009 Nov 19.
PMID: 19926311
Related Citations

Back to top


Cause of death in older men after the diagnosis of prostate cancer.
Authors: Ketchandji M, Kuo YF, Shahinian VB, Goodwin JS
Source: J Am Geriatr Soc, 2009 Jan;57(1), p. 24-30.
EPub date: 2008 Nov 18.
PMID: 19054189
Related Citations

Back to top


Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer.
Authors: Kuo YF, Goodwin JS, Shahinian VB
Source: BMC Health Serv Res, 2008 Jul 14;8, p. 146.
EPub date: 2008 Jul 14.
PMID: 18620606
Related Citations

Back to top


Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer.
Authors: Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS
Source: J Clin Oncol, 2007 Dec 1;25(34), p. 5359-65.
PMID: 18048816
Related Citations

Back to top


Comparison of stage at diagnosis of cancer in patients who are on dialysis versus the general population.
Authors: Taneja S, Mandayam S, Kayani ZZ, Kuo YF, Shahinian VB
Source: Clin J Am Soc Nephrol, 2007 Sep;2(5), p. 1008-13.
EPub date: 2007 Aug 16.
PMID: 17702737
Related Citations

Back to top


Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.
Authors: Shahinian VB, Kuo YF, Freeman JL, Goodwin JS
Source: J Natl Cancer Inst, 2006 Jun 21;98(12), p. 839-45.
PMID: 16788157
Related Citations

Back to top


Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer.
Authors: Shahinian VB, Kuo YF, Freeman JL, Goodwin JS
Source: Arch Intern Med, 2006 Feb 27;166(4), p. 465-71.
PMID: 16505268
Related Citations

Back to top